Correlation Between Cardiometabolic Index and Microalbuminuria in Type 2 Diabetic Patients

Xi Yang  
the Affiliated Hospital of Southwest Medical University

YueFei Jiang  
the Affiliated Hospital of Southwest Medical University

XinLin Hao  
the Affiliated Hospital of Southwest Medical University

XiaoLing Cheng  
the Affiliated Hospital of Southwest Medical University

Qin Wan (wanqin3@163.com)  
the Affiliated Hospital of Southwest Medical University

Research Article

Keywords: Type 2 diabetes, Cardiometabolic index, dyslipidemia, obesity, urinary albumin-to-creatinine ratio, microalbuminuria

Posted Date: September 29th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-936481/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: In recent years, cardiometabolic index (CMI) has been introduced to predict the risk of diabetes in the general population and is also strongly associated with cardiovascular disease, hypertension, and ischemic stroke, but the relationship between CMI and diabetic microalbuminuria remains unclear. This study intends to investigate the relationship between CMI and microalbuminuria in patients with type 2 diabetes mellitus (T2DM).

Methods: 524 subjects (mean age 57.28 ± 10.52 years, 283 males and 241 females) from the Department of Endocrinology, Southwestern Medical University Hospital, China (data collected from June 2017 to June 2019) participated in this study. CMI was calculated by triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C) multiply waist-to-height ratio (WHtR). Microalbuminuria was identified by the urinary albumin-to-creatinine ratio (UACR) when the value was between 30–300 mg/g. Multivariate logistic regression aimed to explore the association between CMI and diabetic microalbuminuria; The receiver operating characteristic (ROC) analysis was employed to evaluate the predictive value of CMI for microalbuminuria in T2DM patients.

Results: The prevalence of microalbuminuria in all participants was 37.8% in men and 41.1% in women. Regardless of gender, CMI was significantly more unfavorable in the microalbuminuria group. The incidence of microalbuminuria increased dose-responsively with increasing CMI quartiles. Modeling CMI as a continuous variable in a multivariate-adjusted model, we observed an independent effect of each 1 SD increase in CMI on the risk of developing microalbuminuria. The relationship was more pronounced in women than in men. In women, the odds ratio (OR) for microalbuminuria was 5.66 (95% CI: 2.247-14.289) in the highest quartile of CMI compared with the lowest quartile; in men, the OR was nearly 4-fold increased (OR: 4.667, 95% CI: 1.910-11.405) in the same situation. The AUC for CMI was 0.681 (0.613 to 0.749) in women and 0.648 (0.582-0.713) in men.

Conclusion: High levels of CMI were independently associated with diabetic microalbuminuria, and CMI, a novel index covering lipids and central obesity, explained the gender differences in obesity-related microalbuminuria excretion, an effect that was substantially increased in women. The results of this study provide important insights into the potential usefulness and clinical relevance of CMI for microalbuminuria in Chinese patients with T2DM.

Registration number: ChiCTR2100047930

Date of registration: On June 27, 2021 (retrospectively registered)

Background

Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes mellitus, the incidence of which has continued to rise in recent years and has become a significant hazard in the development of end-stage renal disease in diabetic patients. It is well known that the presence of microalbuminuria is a marker for the diagnosis of early diabetic nephropathy in T2DM. Considering that early detection of microalbuminuria is an essential factor in avoiding progressive renal function deterioration in diabetic patients. Therefore, early detection of microalbuminuria and timely and effective treatment is key to delaying the progression of diabetic nephropathy, preventing end-stage renal disease, and improving the overall prognosis. It has been widely reported in the literature that central obesity and its associated abnormal lipid metabolism in T2DM patients play an essential role in the process of renal damage, causing nonspecific low-grade inflammation and insulin resistance through the secretion of various inflammatory factors and hormones, leading to renal vascular endothelial dysfunction and the production of albuminuria [1–2]. Dyslipidemia in patients with T2DM is often manifested by high triglyceride (TG) levels and low high-density lipoprotein cholesterol (HDL-C) levels and elevated TG is positively associated with the risk of developing microalbuminuria in T2DM [3]. Also, BMI and WC have been recognized to have a clear relationship with microalbuminuria, but they are less helpful in diagnosing the disease because they do not distinguish between fat and muscle weight or fat distribution [4]. Waist height ratio (WHtR), another anthropometric indicator of central obesity, modifies the relationship between waist circumference and height, is superior to general obesity indicators in predicting the risk of microalbuminuria [5]. Cardiometabolic index (CMI) represents a combination of TG/HDL-C and WHtR, taking lipid and abdominal obesity indicators into account. As a new and widely recognized metabolic index in
recent years, it has been found to predict the risk of diabetes in the general population and is associated with cardiovascular disease, hypertension, and ischemic stroke [6–9]. In this paper, we investigated the correlation between CMI and microalbuminuria in type 2 diabetes in China and aimed to assess the diagnostic value of CMI on the occurrence of microalbuminuria in T2DM and provide a reference for clinical work. To the best of our knowledge, this has not been investigated.

Methods

Study population

A retrospective cross-sectional study was designed and conducted to describe the prevalence and risk factors for developing microalbuminuria in 524 T2DM patients (age ≥ 20 years) hospitalized in the Department of Endocrinology at the Southwestern Medical University Hospital between June 2017 and June 2019. Complete details of the study design and rationale are extensively described elsewhere. Exclusion criteria for this study were as follows: 1) other specific types of diabetes; 2) acute complications of diabetes; 3) renal disease due to primary or secondary nephritis, urinary tract infection, acute and chronic renal failure; 4) severe liver and cardiac dysfunction; 5) acute infection; 6) immunodeficiency, tumor, use of lipid-regulating drugs within the past 3 months and/or angiotensin-converting enzyme inhibitors (ACEI) / angiotensin receptor antagonist (ARB) within the past 3 months. A total of 524 patients were recruited for this study. The study protocol followed the Second Declaration of Helsinki, and the Ethics Committee of Southwest Medical University (Sichuan) approved the study protocol. We obtained written informed consent from each participant before enrollment, and the entire data and procedures were under the principles of ethical standards.

Data collection and measurements

Questionnaire: Specially trained and tested doctors and nurses at our hospital were allowed to administer the questionnaire. We used a well-designed questionnaire to collect data from all patients. A central steering committee and a subcommittee performed quality control of the information collection process. The questionnaire covered the following data: age, gender, duration of diabetes, history of hypertension and diabetes, smoking and alcohol consumption, and use of insulin and antihypertensive medication.

Anthropometric measurements: All patients had to rest quietly for 5 minutes, and then blood pressure was measured by a specially trained professional physician and nurse, and three consecutive readings were recorded and averaged. Other than that, they were asked to dress very lightly, barefoot, and measure their standard weight to the nearest 0.1 kg using a calibrated digital scale; maintain a standing position and quantify their standard height to the nearest 0.1 cm using a calibrated telemetry device, and measure their waist circumference with a flexible tape measure at the level of 1 cm above the umbilicus. All measurements were performed twice and averaged for analysis. BMI was calculated as weight per height squared (kg/m²). WHtR was defined as WC divided by height in meters.

Measurement of experimental indicators: Fasting blood was collected by venipuncture after a brief fast (overnight for 8 hours). Fasting blood glucose (FPG) was measured by the glucose oxidase method; glycated hemoglobin (HbA1c) was measured by high-performance liquid chromatography. A fully automated biochemical analyzer (Hitachi, 7600) was used to detect blood uric acid (SUA), blood creatinine (Scr), urea nitrogen (BUN), aspartate aminotransferase (ALT), alanine aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamine transferase (γ-GGT), TG, total cholesterol (TC), HDL-C, and low-density lipoprotein cholesterol (LDL-C). The 1st-morning urine was retained, and the urinary albumin/creatinine ratio (UACR) was measured by immunoturbidimetric assay. TG/HDL-C ratio was calculated using available TG and HDL-C values. All laboratory equipment was calibrated, and double-blind samples were used.

Definitions
CMI was obtained by the following formula [6]: \( \text{CMI} = \frac{\text{TG}}{\text{HDL-C}} \times \text{WHtR} \). Lipid accumulation product (LAP) was calculated according to the gender-specific formula [10]: female \( \text{LAP} = \text{TG} \times (\text{WC} \, \text{cm} - 58) \) and male \( \text{LAP} = \text{TG} \times (\text{WC} \, \text{cm} - 65) \). Normoalbuminuria was defined as \( \text{UACR} < 30 \, \text{mg/g} \); microalbuminuria was defined as \( 30 \, \text{mg/g} \leq \text{UACR} < 300 \, \text{mg/g} \) [11]. Hypertension was diagnosed as mean systolic blood pressure (SBP) equal to or greater than 140 mm Hg and/or diastolic blood pressure (DBP) of at least 90 mm Hg and/or the participant was taking antihypertensive medication or self-reported previously diagnosed hypertension [12]. Diagnosis of diabetes according to the American Diabetes Association criteria: fasting plasma glucose (FPG) \( \geq 7.0 \, \text{mmol/L} \) and/or self-reported history of previous diagnosis or treatment with plasma glucose-lowering [13].

**Statistical analyses**

Analyses were performed in a gender-specific manner using SPSS 25.0 software. Normally distributed measures were expressed as mean±standard deviation (x±s), and comparisons between the 4 groups were made using one-way ANOVA, and 2-pair comparisons between groups were made using the LSD-t-test. Non-normally distributed measures were expressed as M(Q1, Q3), and comparisons between 4 groups were made using Kruskal-Wallis H-test, and comparisons between 2 pairs of groups were made using Nemenyi's method. Categorical variables were expressed as frequencies (%), and comparisons were made using the \( \chi^2 \) test. Multiple logistic regression analysis was used to explore the association between CMI (When included in the analysis as a continuous or a categorical variable, respectively) and diabetic microalbuminuria and to obtain a sex-specific dominance ratio (OR) for each SD change in CMI to determine the risk of microalbuminuria in T2DM, with results shown as ORs and 95% confidence intervals (95% CI). Finally, the optimal cut-off value for CMI was investigated using subject operating characteristic (ROC) curves to detect the presence of microalbuminuria. The area under the curve (AUC) was used to compare the ability of CMI to discriminate microalbuminuria with other indicators. Differences were considered statistically significant at P<0.05.

**Results**

**Demographics, physical measurements values, and laboratory indices of all study participants (Table 1, Table at the end of the article)**

We included a total of 524 patients with confirmed T2DM, with a mean age of 57.28 ± 10.52 years, with a higher mean age in women than in men, 46% were female, and both men and women had microalbuminuria older than their age group. Among men, 37.8% of T2DM patients had microalbuminuria, while the percentage of women with microalbuminuria was higher at 41.1%. Regarding physical measurements, regardless of gender, patients with microalbuminuria had significantly higher BMI, WC, SBP, DBP, and VFA than the group without microalbuminuria, and they had a longer duration of diabetes, substantially longer in women than in men. Laboratory index results showed that FPG, HbA1c, ALT, AST, and \( \lambda \)GGT were significantly higher in the male patients in the group with microalbuminuria. Regardless of gender, WHtR, TG, and TG/HDL-C were considerably higher in the microalbuminuria group, and HDL-C was significantly lower than in the regular urine albumin group. Among all subjects, smoking prevalence was significantly higher in men than in women, while female patients tended not to smoke and men showed significant differences in smoking status. Hypertension prevalence and antihypertensive medication use were more common in the group with microalbuminuria but differed significantly in female patients. Also, not surprisingly, CMI and LAP were increased dramatically in patients with microalbuminuria.

**Dominance ratios (OR) and 95% confidence intervals for patients with microalbuminuria in T2DM according to sex-specific continuous variables or quartiles of CMI and LAP (Table 2, Table at the end of the article)**

Multiple logistic regression analysis was performed to assess the gender-specific associations of CMI and LAP with microalbuminuria. CMI and LAP were included in the analysis as continuous variables, and the results showed that the risk of microalbuminuria increased by 48% and 59% for each SD increase in CMI level in men and women, respectively. The association between CMI and microalbuminuria was significant and robust, more pronounced in women (women, OR, 1.586;
95% CI, 1.181-2.128; men, OR, 1.480; 95% CI, 1.206-1.816). While we took CMI and LAP as categorical variables into the multiple logistic regression analysis and used age, SBP, DBP, BMI, and WC as confounding factors (model 2), then found that in female subjects, the risk of microalbuminuria in the highest quartile of CMI and LAP was 5.83 times (95% CI, 2.38 to 14.32) and 9.16 times (95% CI, 3.04 to 27.54) of those in the lowest quartile, respectively. In model 3, we further included FPG, HbA1C, history of hypertension, antihypertensive medication, and history of insulin use, and the results did not show substantial changes, and the correlation between CMI and LAP and microalbuminuria remained significant. Thus, higher CMI and LAP levels in women were independently and positively associated with the prevalence of microalbuminuria in a dose-response pattern (P<0.001). Furthermore, we found a 4.67-fold increase in the OR of microalbuminuria in men with higher CMI quartile levels (95% CI, 1.910 to 11.405; P<0.001), whereas LAP was not significantly associated with the prevalence of microalbuminuria after inclusion of confounding factor analysis (P=0.141). Overall, the association of CMI and LAP with microalbuminuria was more prominent in female patients.

**ROC curves of different metabolic indicators predicting the production of microalbuminuria in patients with T2DM (Table 3, Table at the end of the article)**

ROC analysis showed that the AUC value of CMI was significant for identifying Type 2 diabetic patients with microalbuminuria, and the results are summarized in Table 3. In women, we found that CMI had the largest AUC (AUC: 0.681, 95% CI: 0.613-0.749) among the indices, statistically close to LAP (AUC: 0.676, 95% CI: 0.609-0.744) and significantly higher than BMI (AUC 0.681 vs. 0.600, P = 0.008) and WC (AUC 0.681 vs. 0.587, P = 0.021), and CMI was also superior to TG/HDL-C alone (AUC: 0.671, 95% CI: 0.601-0.740) and WHtR (AUC 0.599. 95% CI:0.528-0.671). Meanwhile, CMI showed a strong sensitivity of 80.8% but a specificity of only 47.9%. In men, the AUC of CMI (AUC: 0.648, 95% CI: 0.582-0.713) was higher than LAP (AUC 0.648 vs 0.645, < 0.001) and significantly greater than BMI (AUC 0.648 vs 0.599, P = 0.005) and WC (AUC 0.648 vs 0.582, P = 0.021). However, CMI showed lower sensitivity (68.0%) versus specificity (54%) in men.

**Discussion**

We found that CMI, a novel metabolic index that expresses both dyslipidemias and accurately reflects central obesity status, was significantly and independently associated with the risk of developing microalbuminuria in Chinese patients with type 2 diabetes. The findings reveal the potential of CMI as a screening marker for microalbuminuria in patients with T2DM, demonstrating that CMI is a crucial independent determinant of early diabetic nephropathy and has important implications for exploring potential areas of research targeting CMI in the future, especially for delaying the progression of diabetic nephropathy and reducing the risk of developing end-stage renal disease. Patients with T2DM are often associated with dyslipidemia and central obesity. Previous studies have shown that individuals with abnormal lipid metabolism and obesity have worse metabolic profiles and poorer renal outcomes [14]. In patients with early-stage chronic kidney disease, dyslipidemia is mainly characterized by atherogenic dyslipidemia: high TG levels, low HDL-C levels, and increased concentrations of small, dense, low-density lipoprotein (sdLDL) particles [15]. Cao et al. [16] showed that high TG levels are an essential risk factor for kidney damage, and the adjusted risk of any renal event associated with increased TG levels remains high. sd-LDL is a vital lipid indicator in diabetic dyslipidemia [17], and TG/HDL-C is thought to reflect the level of "sd-LDL" particles. Because of the combination of TG and HDL-C levels, TG/HDL-C is valuable in differentiating microalbuminuria. Wen et al. [18] found that elevated TG/HDL-C was significantly associated with microalbuminuria excretion in Chinese patients with type 2 diabetes. A study of Japanese diabetic patients showed a significant decrease in LDL particle size and a considerable increase in the TG/HDL-C ratio in patients with nephropathy than subjects without nephropathy [19]. As our hypothesis in general, TG/HDL-C performed better in predicting proteinuria/chronic kidney disease compared to non-HDL-C/HDL-C, TG, and HDL-C [20].

Obesity is considered to be an essential risk factor for the development of renal damage in T2DM. Data from the Framingham Heart Study, which included more than 2600 patients without chronic kidney disease at baseline, showed that...
Obese patients were at increased risk of developing stage 3 chronic kidney disease (BMI $\geq 30 \text{ kg/m}^2$) compared to non-obese subjects [21]. Several independent studies have shown that anthropometric measures representing central obesity are superior to general obesity indicators in predicting the development of microalbuminuria in T2DM [22-25]. As tools for detecting central obesity, BMI and WC have a clear relationship with the excretion of microalbuminuria. Still, neither can distinguish between SAT and VAT, especially for Asians, as they are not suitable for diagnosing early diabetic nephropathy because Asians are more prone to visceral fat accumulation and insulin resistance [26, 27]. KB et al. found that individuals with chronic kidney disease had higher WC and WHtR; however, only WHtR showed a relationship with reduced eGFR and albuminuria excretion, possibly due to different criteria for WC values in individuals of different heights. WHtR corrects WC for height and better reflects abdominal obesity in people of other races, ages, and genders [28-30].

Cardiometabolic index (CMI) is a new index calculated from TG/HDL-C and WHtR, which was proposed by Ichiro Wakabayashi in 2015 [6]. It can better reflect the status of diabetes mellitus and the progression of atherosclerosis [31-32]. As a new indicator of visceral adipose tissue distribution and dysfunction, CMI has been closely associated with various diseases since its introduction [33-35]. In T2DM, considering that insulin resistance, inflammatory response, and abnormal lipid metabolism are inextricably linked to microalbuminuria production, we speculate that CMI is associated with microalbuminuria excretion and may serve as a novel screening index for early diabetic nephropathy. This paper is the first to explore the predictive value of CMI and other lipid and obesity indicators for the development of microalbuminuria in diabetic patients in a Chinese type 2 diabetic population.

We included CMI and LAP as categorical variables in our analysis and found that both had a more significant effect on early kidney damage in women compared to men, but the impact of LAP appeared to be more powerful. After excluding the impact of confounding factors, the risk of developing microalbuminuria in men with T2DM increased significantly with increasing quartiles of CMI, independent of LAP. In a cross-sectional study of 5398 healthy Koreans over 20 years of age, in general, the urinary albumin/creatinine ratio increased with increasing CMI levels, and that CMI was associated with increased glucose and urinary albumin/creatinine ratio increased were independently correlated [36]. Wang et al. also concluded that CMI reflects the visceral fat area and the pathological process leading to impaired renal function and can be used as a screening marker for CKD [37]. Our study confirmed that the risk of developing microalbuminuria increased proportionally with changes in CMI quartiles, and CMI showed a strong correlation with microalbuminuria excretion in T2DM. Although the ORs for the risk of developing CMI were weaker than LAP, considering that LAP does not include HDL-C, an essential indicator of dyslipidemia, in its calculations for analysis, and that people of different heights should have other WC criteria, it neglects the role of height. It, therefore, has limited value as a test indicator for combined microalbuminuria in patients with T2DM [38].

To distinguish the predictive value of CMI from lipid and obesity indicators as screening markers for diabetic microalbuminuria, we analyzed T2DM patients of both sexes separately using ROC curves. We found that CMI had the most significant AUC value in female patients. Although its discriminatory power was not significantly greater than LAP, it had a more comprehensive diagnostic significance considering that CMI covered both HDL-C and height-specific indicators. Surprisingly, CMI and LAP showed better predictive effects in women, but both TG/HDL-C and WHtR had larger AUC values than WC. This cause may be related to the smaller number of our subjects. Similarly, the AUC value of CMI was still the largest in male patients; however, the sensitivity of CMI was only 68%, and the specificity was even lower at 54.00%. Compared to men, CMI is much more sensitive than LAP in women, so CMI values are more valuable for diagnosing microalbumin excretion in women with T2DM. In conclusion, CMI has a robust discriminatory ability and high sensitivity and can be an economic screening index for screening people with T2DM combined with microalbuminuria.

Our study found that CMI and LAP are of clinical value as new metabolic indicators in assessing the risk of developing microalbuminuria in type 2 diabetes and differ by gender. The deleterious effect of CMI on early diabetic nephropathy was more significant in women compared to men. Our findings are consistent with previous clinical studies in which abnormal lipid metabolism and central obesity triggered microalbuminuria excretion, particularly in female patients with T2DM. A

Page 6/16
study based on the Korean National Health and Nutrition Examination Survey found that obese female patients were more likely to develop microalbuminuria and that impaired fasting glucose and high triglycerides were significant correlates of microalbuminuria [39]. The interaction of increased glucose exposure with abnormal lipid metabolism associated with central obesity may be one of the leading causes of vascular endothelial dysfunction and microalbuminuria excretion in a 5398 Korean general population [40]. Based on a retrospective observational study of renal injury in elderly participants in a Chinese community, researchers hypothesized that female patients with high TG and high WC levels were significantly associated with microalbuminuria excretion[41]. In conjunction with our findings, we showed that the statistical effect of visceral fat distribution on microalbuminuria excretion in female T2DM patients manifested itself as a significant effect of CMI and LAP. The reason for this outcome may be the dysregulation of macrophage and adipocyte secretion in patients with T2DM, which produces a variety of hormones and pro-inflammatory factors, leading to a low inflammatory response, insulin resistance, dyslipidemia, and/or increased synthesis of vasoactive and fibrogenic substances [42-46]. Their complex interactions may negatively affect the vascular endothelium and impair renal function, thus causing the production of microalbuminuria. In addition, considering that most of the female patients we included were postmenopausal women with decreased sex hormones, the beneficial effects of estrogen on the kidney were inevitably lost. Estrogen is thought to reduce proteinuria, glomerulosclerosis, and tubulointerstitial fibrosis [47-49]. Possible mechanisms are: (i) in diabetic patients, (estradiol) E2 attenuates glomerulosclerosis and tubulointerstitial fibrosis by reducing type I and type IV collagen synthesis, increasing matrix metalloproteinase expression, and inhibiting apoptosis [50-52]; (ii) E2 reduces the angiotensin type II1 receptor expression, transforming growth factor-β and endothelin-1 and regulating vascular dysfunction; (iii) E2 has also been shown to upregulate nitric oxide synthase activity and vascular endothelial growth factor expression in glomeruli and improve vascular permeability, thereby potentially reducing the loss of glomerular function in progressive chronic kidney disease, including diabetic nephropathy [53-56].

This study still has some limitations: (1) This study is a cross-sectional study, and this study can only provide evidence about the strong correlation between CMI and LAP and microalbuminuria. Still, it cannot further elucidate the causal relationship between CMI, LAP, and microalbuminuria in patients with T2DM, which needs to be further verified by a large follow-up study. (2) The sample size was small and limited by the region, and data we only collected from some patients in southwest China with a single ethnicity, so more studies are needed to investigate whether the findings apply to different regions or ethnic groups. (3) There are too many confounding factors affecting microalbuminuria excretion, and the effects of confounding factors were not eliminated when conducting the analysis, which may produce some data bias.

**Conclusion**

In summary, our study reveals for the first time an association between CMI and microalbuminuria in type 2 diabetes that is independent of prevalent CVD, medication use, and traditional cardiovascular risk factors. Thus, these data provide strong evidence for a unique, independent, and economic role of CMI in high-burden nephropathy. These findings have important implications for guiding original prevention and understanding the mechanisms of VAT-mediated kidney injury.

**Abbreviations**

AUC: Area under the curve; ROC: Receiver operating characteristic curve; CI: Confidence interval; SD: Standard deviation; ORs: Odds ratios; CMI: Cardiometabolic index; LAP: Lipid accumulation product; T2DM: Type 2 diabetes mellitus; UACR: Urinary albumin to creatinine ratio; DBP: Diastolic blood pressure; SBP: Systolic blood pressure; FPG: Fasting plasma glucose; SFA: Subcutaneous fat area; VFA: Visceral fat area; TG: Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG/HDL-C: Triglyceride to high-density lipoprotein cholesterol ratio; WHtR: Waist to height ratio; WC: Waist circumference; BMI: Body mass index; HbA1c(%): Glycated hemoglobin; SUA: Serum uric acid; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphate; λGGT U/L: Gammaglutamine aminotransferase;
Declarations

Ethics approval and consent to participate

This study was performed in compliance with the ethical principle of the Declaration of Helsinki. Written informed consents were acquired from all participants and all procedures were performed by the ethical standards. The Ethics Committee of Southwest Medical University (Luzhou, China) approved the study protocol. reference number 2018017.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by grants from the "Metabolic Disease Cohort Study" program funds (The National Key Research and Development Program of China, Grant#2016YFC0901200, 2016YFC0901205). The founder provided financial support for our survey, but do not interfere with the design, operation, and analysis of the study.

Authors’ contributions

In this study, XY did the study design, statistical analyses, and results in interpretation. YFJ, XLH, and XLC participated in analyzing and resolving difficulties of analytic strategies and results in discussion. Finally, QW functioned as a final reviewer who gave constructional suggestions for the interpretation of data. The corresponding author was QW. All authors have read and approved the manuscript.

Acknowledgments

We would like to express our gratitude to all those who exert their effects in achieving this study.

Author Details

1Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Jiangyang District, Luzhou 646000, Sichuan, People’s Republic of China.

2Department of Endocrinology, Chengdu Seventh People’s Hospital, 1 Twelve Middle Street, Wuhou District, Chengdu 610041, Sichuan, People’s Republic of China.

3Department of Endocrinology, Dujiangyan City People’s Hospital, 622 Baolian Road, Dujiangyan 611830, Sichuan, People’s Republic of China.

4Department of Endocrinology, Luohu People’s Hospital, 47 Youyi Road, Luohu District, Shenzhen 518001, People’s Republic of China.

References
1. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease. Int J Mol Sci. 2014; 15:6184–223.

2. Gnudi L, Coward RJM, Long DA. Diabetic nephropathy: a perspective on novel molecular mechanisms. Trends Endocrinol Metab. 2016;27:820–30.

3. Srinivasan S, Singh P, Kullothungan V, Sharma T, Raman R. Relationship between triglyceride glucose index, retinopathy and nephropathy in Type 2 diabetes. Endocrinol Diabetes Metab. 2020;4(1):e00151.

4. Soto González A, Bellido D, Buño MM, Pértega S, De Luis D, Martínez-Olmos M, Vidal O. Predictors of the metabolic syndrome and correlation with computed axial tomography. Nutrition. 2007 Jan;23(1):36-45.

5. Man REK, Gan ATL, Fenwick EK, Gupta P, Wong MYZ, Wong TY, Teo BW, Sabanayagam C, Lamoureux EL. The Relationship between Generalized and Abdominal Obesity with Diabetic Kidney Disease in Type 2 Diabetes: A Multiethnic Asian Study and Meta-Analysis. Nutrients. 2018 Nov 5;10(11):1685.

6. Wakabayashi I, Daemon T. The "cardiometabolic index" as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta. 2015;438:274-278.

7. Wang H, Chen Y, Sun G, Jia P, Qian H, Sun Y. Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting the risk of hypertension in Chinese population. Postgrad Med. 2018 Apr;130(3):325-333.

8. Wang H, Sun Y, Li Z, Guo X, Chen S, Ye N, Tian Y, Zhang L. Gender-specific contribution of the cardiometabolic index and lipid accumulation product to left ventricular geometry change in a general population of rural China. BMC Cardiovasc Disord. 2018 Apr 10;18(1):62.

9. Wang H, Chen Y, Guo X, Chang Y, Sun Y. Usefulness of the cardiometabolic index for the estimation of ischemic stroke risk among the general population in rural China. Postgrad Med. 2017 Nov;129(8):834-841.

10. Kahn H. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26.

11. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rosset J, De Zeeuw D, Hostetter TH, Laneire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005 Jun;67(6):2089-100.

12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72.

13. American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care. 2015 Jan;38 Suppl: S8-S16.

14. Palazhy S, Viswanathan V. Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy. Diabetes Metab J. 2017 Apr;41(2):128-134.

15. Kajingulu FM, Lepira FB, Mbutiwi FI, Makulo JR, Sumaili EK, Bukabau JB, Mokoli VM, Longo AL, Nseka NM. Albuminuria status and patterns of dyslipidemia among type 2 diabetes black patients managed at a tertiary health-care hospital: A Post hoc analysis. Saudi J Kidney Dis Transpl. 2018 May-Jun;29(3):649-657.

16. Cao Y, Sun G, Liu R, Sun A, Zhang Q, Li Y, Wang L, Chao X, Zhou X, Zhang S, Chen R. Plasma triglyceride levels and central obesity predict the development of kidney injury in Chinese community older adults. Ren Fail. 2019 Nov;41(1):946-953.

17. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma. Clin Biochem. 2001;34:583–8.

18. Wen J, Yuan H. Independent association between the visceral adiposity index and microalbuminuria in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2020 Jan;36(1):e3198.
19. Hirano T, Naito H, Kurokawa M, Ebara T, Nagano S, Adachi M, Yoshino G. High prevalence of small LDL particles in noninsulin-dependent diabetic patients with nephropathy. Atherosclerosis 1996;123:57-72

20. Wen J, Chen Y, Huang Y, Lu Y, Liu X, Zhou H, Yuan H. Association of the TG/HDL-C and Non-HDL-C/HDL-C Ratios with Chronic Kidney Disease in an Adult Chinese Population. Kidney Blood Press Res. 2017;42(6):1141-1154.

21. Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS, Levy D, Fox CS. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis. 2008 Jul;52(1):39-48.

22. Lundgren H, Bengtsson C, Blohm G, Lapidus L, Sjöström L. Adiposity and adipose tissue distribution in relation to incidence of diabetes in women: results from a prospective population study in Gothenburg, Sweden. Int J Obes. 1989;13(4):413-23.

23. Warne DK, Charles MA, Hanson RL, Jacobsson LT, McCance DR, Knowler WC, Pettitt DJ. Comparison of body size measurements as predictors of NIDDM in Pima Indians. Diabetes Care. 1995 Apr;18(4):435-9.

24. Tulloch-Reid MK, Williams DE, Looker HC, Hanson RL, Knowler WC. Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians. Diabetes Care. 2003 Sep;26(9):2556-61.

25. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005 Mar;81(3):555-63.

26. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and each other in their body mass index/body fat percent relationship. Obes Rev. 2002;3:141-146.

27. Nazare JA, Smith JD, Borel AL, Haffner SM, Balkau B, Ross R, Massien C, Almêras N, Després JP. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. Am J Clin Nutr. 2012 Oct;96(4):714-26.

28. Stuhrdrehre WL, Becker DJ, Drash AL, Ellis D, Kuller LH, Wolfson SK, Orchard TJ. The association of waist/hip ratio with diabetes complications in an adult IDDM population. J Clin Epidemiol. 1994 May;47(5):447-56.

29. Chou CY, Lin CH, Lin CC, Huang CC, Liu CS, Lai SW. Association between waist-to-hip ratio and chronic kidney disease in the elderly. Intern Med J. 2008 Jun;38(6):402-6.

30. Blaslov K, Bulum T, Duvnjak L. Waist-to-height ratio is independently associated with chronic kidney disease in overweight type 2 diabetic patients. Endocr Res. 2015;40(4):194-8.

31. Wakabayashi I, Sotoda Y, Hirooka S, Orita H. Association between cardiometabolic index and atherosclerotic progression in patients with peripheral arterial disease. Clin Chim Acta. 2015 Jun 15;446:231-6.

32. Shi WR, Wang HY, Chen S, Guo XF, Li Z, Sun YX. Estimate of prevalent diabetes from cardiometabolic index in general Chinese population: a community-based study. Lipids Health Dis. 2018 Oct 12;17(1):236.

33. Higashiyama A, Wakabayashi I, Okamura T, Kobukyo Y, Watanabe M, Takegami M, Honda-Kohmo K, Okayama A, Miyamoto Y. The Risk of Fasting Triglycerides and its Related Indices for Ischemic Cardiovascular Diseases in Japanese Community Dwellers: the Suita Study. J Atheroscler Thromb. 2021 May 28.

34. Dursun M, Besiroglu H, Otuncetemur A, Ozbek E. Association between cardiometabolic index and erectile dysfunction: A new index for predicting cardiovascular disease. Kaohsiung J Med Sci. 2016 Dec;32(12):620-623.

35. Liu X, Wu Q, Yan G, Duan J, Chen Z, Yang P, Bragazzi NL, Lu Y, Yuan H. Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype. J Endocrinol Invest. 2021 Jun;44(6):1253-1261.

36. Choi JW, Oh IH, Lee CH, Park JS. Effect of synergistic interaction between abnormal adiposity-related metabolism and prediabetes on microalbuminuria in the general population. PLoS One. 2017 Jul 17;12(7):e0180924.

37. Wang HY, Shi WR, Yi X, Wang SZ, Luan SY, Sun YX. Value of reduced glomerular filtration rate assessment with cardiometabolic index: insights from a population-based Chinese cohort. BMC Nephrol. 2018 Oct 25;19(1):294.
38. Qi L, Kang N, Li Y, Zhao H, Chen S. The Predictive Value of Visceral Adiposity Index and Lipid Accumulation Index for Microalbuminuria in Newly Diagnosed Type 2 Diabetes Patients. Diabetes Metab Syndr Obes. 2021 Mar;11:1107-1115.

39. Rim JH, Lee YH, Cha BS, Lee SG, Kim JH. Central obesity is an independent risk factor for microalbuminuria in both the general Korean women and non-diabetic non-hypertensive subpopulation: Association of microalbuminuria and metabolic syndrome from the Korea National Health and Nutrition Examination Survey 2011-2012. Clin Chim Acta. 2015 Aug 25;448:74-9.

40. Glastras SJ, Chen H, Teh R, McGrath RT, Chen J, Pollock CA, Wong MG, Saad S. Mouse Models of Diabetes, Obesity and Related Kidney Disease. PLoS One. 2016 Aug 31;11(8):e0162131.

41. Cao Y, Sun G, Liu R, Sun A, Zhang Q, Li Y, Wang L, Chao X, Zhou X, Zhang S, Chen R. Plasma triglyceride levels and central obesity predict the development of kidney injury in Chinese community older adults. Ren Fail. 2019 Nov;41(1):946-953.

42. mig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013; 3:957–76.

43. Kurozumi A, Okada Y, Arao T, Tanaka Y. Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus. Intern Med. 2016;55(21):3091-3095.

44. Kim SH, Despres JP, Koh KK. Obesity and cardiovascular disease: friend or foe?. Eur Heart J. 2016;37:3560–8.

45. Wu CC, Liou HH, Su PF, Chang MY, Wang HH, Chen MJ, Hung SY. Abdominal obesity is the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients. Nephrol Dial Transplant. 2011 Nov;26(11):3689-95.

46. Mathew AV, Okada S, Sharma K. Obesity-related kidney disease. Curr Diabetes Rev. 2011; 7:41–9.

47. Potter M, Karl M, Zheng F, Leclercq B, Striker GE, Striker LJ. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol. 2003 May;162(5):1441-8.

48. Mankhey RW, Bhatti F, Maric C. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol. 2005;288:F399–F405.

49. Mankhey R, Wells CC, Bhatti F, Maric C. 17-beta Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2006;292:R769–R777.

50. Potter M, Karl M, Zheng F, Elliot SJ, Striker GE, Striker LJ. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and pro sclerotic response to estrogens. Am J Pathol. 2002 May;160(5):1877-85.

51. Negulescu O, Bognar I, Lei J, Devarajan P, Silbiger S, Neugarten J. Estradiol reverses TGF-beta1-induced mesangial cell apoptosis by a casein kinase 2-dependent mechanism. Kidney Int. 2002 Dec;62(6):1989-98.

52. Blush J, Lei J, Ju W, Silbiger S, Pullman J, Neugarten J. Estradiol reverses renal injury in Alb/TGF-beta1 transgenic mice. Kidney Int. 2004 Dec;66(6):2148-54.

53. Dean SA, Tan J, O’Brien ER, Leenen FH. 17betaEstradiol downregulates tissue angiotensin converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol. 2005;288:R759–R766.

54. Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, Striker GE, Striker LJ. Smoking induces glomerulosclerosis in aging estrogen-deficient mice through cross-talk between TGF-beta1 and IGF-I signaling pathways. J Am Soc Nephrol. 2006 Dec;17(12):3315-24.

55. Gross ML, Adamczak M, Rabe T, Harbi NA, Krtijl J, Koch A, Hamar P, Amann K, Ritz E. Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats. J Am Soc Nephrol. 2004 Feb;15(2):348-58.
Table 1 Characteristics of T2DM with microalbuminuria stratified by sex
| Variables                        | Males (n=283) | Fmales (n=241) | P value* |
|---------------------------------|---------------|----------------|----------|
|                                | Normal albuminuria (n=176) | Microalbuminuria (n=107) | Normal albuminuria (n=142) | Microalbuminuria (n=99) | P value* |
| Age(years)                      | 54.99±10.87   | 56.36±11.14    | 0.309    | 58.96±9.85   | 59.95±9.43   | 0.427    |
| Height(cm)                      | 165.98±5.94   | 165.45±6.43    | 0.477    | 154.27±5.84  | 153.72±5.94  | 0.470    |
| Weight(cm)                      | 68.55±11.30   | 71.11±10.05    | 0.054    | 57.92±9.02   | 61.12±11.32  | 0.016    |
| BMI                             | 24.82±3.43    | 25.98±3.30     | 0.006    | 24.35±3.60   | 25.80±4.08   | 0.004    |
| WC(cm)                          | 88.56±9.96    | 91.58±8.74     | 0.010    | 84.17±10.81  | 87.35±10.03  | 0.021    |
| Hip circumference(cm)           | 94.32±6.84    | 95.21±6.55     | 0.278    | 92.11±7.00   | 93.31±8.39   | 0.226    |
| SBP(mmHg)                       | 130.44±17.42  | 138.42±20.82   | 0.001    | 133.24±19.13 | 145.70±18.35 | <0.001   |
| DBP(mmHg)                       | 79.15±10.15   | 83.19±11.12    | 0.002    | 75.31±9.69   | 80.87±10.17  | <0.001   |
| VFA(cm)                         | 88.84±41.18   | 105.88±46.56   | 0.001    | 84.44±43.73  | 98.61±46.76  | 0.017    |
| SFA(cm)                         | 154.55±58.03  | 167.83±49.25   | 0.049    | 167.07±66.15 | 181.89±70.26 | 0.097    |
| Duration of diabetes (month)    | 40.00±2.75-98.5| 62.00±2.00-147.5| 0.026    | 48.00±1.00-114| 82.00±20.50-122.75| 0.028    |
| FPG (mmol/L)                    | 8.50±6.80-11.55| 9.73±7.50-11.30| 0.038    | 7.80±6.50-10.25| 8.93±6.98-11.10| 0.166    |
| HbA1c%                          | 8.95±7.08-11.53| 9.50±8.40-11.60| 0.035    | 8.70±7.20-11.70| 9.30±7.58-11.10| 0.205    |
| SUA (μmol/L)                    | 345.20±289.80-414.90 | 361.10±296.10-442.80 | 0.173    | 279.60±238.80-334.70 | 301.15±252.75-378.53 | 0.016    |
| ALT(U/L)                        | 24.50±17.60-35.40 | 27.70±19.28-39.83 | 0.049    | 19.50±15.75-27.65 | 19.90±14.90-27.60 | 0.732    |
| AST(U/L)                        | 19.20±16.10-24.60 | 21.65±17.25-30.63 | 0.021    | 19.00±16.33-23.55 | 19.40±14.78-26.10 | 0.693    |
| ALP(U/L)                        | 82.30(64.10-97.60) | 89.65(65.35-106.48) | 0.144    | 77.45(64.20-102.53) | 87.40(72.10-107.60) | 0.021    |
| λGGT(U/L)                       | 25.40(17.70-40.80) | 36.40(23.58-69.90) | <0.001   | 19.20(12.70-30.28) | 21.40(15.70-36.70) | 0.090    |
| TG(μmol/L)                      | 1.61(1.14-2.55) | 2.29(1.58-4.10) | <0.001   | 1.60(1.14-2.24) | 2.12(1.54-3.26) | <0.001   |
| TC(μmol/L)                      | 4.56(3.73-5.23) | 4.57(3.83-5.48) | 0.283    | 4.69(3.90-5.45) | 4.69(4.04-5.70) | 0.297    |
| HDL-C(μmol/L)                   | 1.04(0.87-1.30) | 0.97(0.84-1.19) | 0.031    | 1.25(1.04-1.49) | 1.09(0.92-1.24) | <0.001   |
| LDL-C(μmol/L)                   | 2.75±2.03-3.47 | 2.44±1.85-3.23 | 0.095    | 2.84±2.20-3.53 | 2.71±2.14-3.52 | 0.651    |
| TG/HDL-C                        | 1.61±1.02-2.23±1.45-4.09 | <0.001 | 1.33±0.86-2.08±1.27-3.44 | <0.001 |
|                  | Sex A                        | Sex B                        | p     | Sex A                        | Sex B                        | p     |
|------------------|------------------------------|------------------------------|-------|------------------------------|------------------------------|-------|
| WHtR             | 0.53±0.06                    | 0.55±0.06                    | 0.004 | 0.55±0.07                    | 0.57±0.07                    | 0.015 |
| LAP              | 40.00 (22.30-72.88)          | 55.80 (35.25-126.72)        | <0.001| 37.88 (22.25-70.16)          | 63.72 (41.10-94.12)          | <0.001|
| CMI              | 0.85 (0.54-1.48)             | 1.15 (0.81-2.36)            | <0.001| 0.72 (0.46-1.15)             | 1.20 (0.74-1.85)             | <0.001|
| Hypertension (%) | 58±33.0                      | 45±42.1                     | 0.123 | 53±37.3                     | 60±60.6                     | <0.001|
| Anti-hypertensive drug (%) | 50±28.4 | 37±32.9 | 0.275 | 47±33.1 | 54±54.5 | 0.001 |
| History of insulin use (%) | 48±27.3 | 38±35.5 | 0.144 | 38±26.8 | 37±37.4 | 0.080 |
| Current smoker (%) | 83±47.2 | 69±64.5 | 0.005 | 30±2.1 | 0±0 | 0.146 |
| Current drinker (%) | 101±57.4 | 65±60.7 | 0.578 | 13±9.2 | 6±6.1 | 0.381 |
| Lipid-lowering drug (%) | 17±9.7 | 15±14.0 | 0.261 | 13±9.2 | 14±14.1 | 1.458 |

Data are expressed as mean ± standard deviation (SD) or median (interquartile range) and numbers (percentage) as appropriate. CMI: cardiometabolic index, LAP: lipid accumulation product, DBP: diastolic blood pressure, SBP: systolic blood pressure, FPG: fasting plasma glucose, SFA: subcutaneous fat area, VFA: visceral fat area, TC: total cholesterol, HDL-C: high density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TG/HDL-C: triglyceride to high density lipoprotein cholesterol ratio, WHtR: waist to height ratio, WC: waist circumference, BMI: body mass index, HbA1c (%): glycated hemoglobin, SUA: serum uric acid, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphate, AGT: gammaglutamine aminotransferase.

*Comparisons of category variables between groups were tested by chi-square test or rank-sum test (ordinal category variables) and comparisons for continuous variables between groups were tested by Student’s t or Mann-Whitney test.

Table 2: Sex-specific logistic regression models for microalbuminuria with CMI.
| Variables                  | Diabetic microalbuminuria |
|----------------------------|---------------------------|
|                            | OR(95%CI)                 |
|                            | Case(%)                   |
|                            | Model1                    |
|                            | Model2                    |
|                            | Model3                    |
| **Males**                  |                           |
| CMI(Per 1 SD increase)     | 1.444(1.205-1.729)        |
| **P value for trend**      | 0.001                     |
| Quartiles of CMI           |                           |
| Q1                         | 14(13.1)                  |
| Q2                         | 26(24.3)                  |
| Q3                         | 31(29.0)                  |
| Q4                         | 36(33.6)                  |
| LAP(Per 1 SD increase)     | 1.009(1.005-1.013)        |
| **P value for trend**      | 0.001                     |
| Quartiles of LAP           |                           |
| q1                         | 16(15.0)                  |
| q2                         | 26(24.3)                  |
| q3                         | 30(28.0)                  |
| q4                         | 35(32.7)                  |
| **Females**                |                           |
| CMI(Per 1 SD increase)     | 1.693(1.285-2.230)        |
| **P value for trend**      | 0.001                     |
| Quartiles of CMI           |                           |
| Q1                         | 12(12.1)                  |
| Q2                         | 24(24.2)                  |
| Q3                         | 27(27.3)                  |
| Q4                         | 36(36.4)                  |
| LAP(Per 1 SD increase)     | 1.010(1.004-1.015)        |
| **P value for trend**      | 0.001                     |
| Quartiles of LAP           |                           |
| q1                         | 10(10.1)                  |
| q2                         | 26(26.3)                  |

Page 15/16
|    | AUC (95%CI) | P value | Cut-off according to Youden's index | Sensitivity (%) | Specificity (%) |
|----|-------------|---------|-------------------------------------|-----------------|-----------------|
| **Males** |   |   |   |   |   |
| CMI | 0.648(0.582-0.713) | < 0.001 | >0.89 | 68% | 54.00% |
| LAP | 0.645(0.579-0.711) | < 0.001 | >32.40 | 82.20% | 41.50% |
| BMI | 0.599(0.532-0.666) | 0.005 | >23.85 | 77.60% | 39.80% |
| WC | 0.582(0.515-0.649) | 0.021 | >83.5 | 85.00% | 29.50% |
| WHtR | 0.592(0.524-0.660) | 0.009 | >0.52 | 74.80% | 41.50% |
| TG/HDL-C | 0.645(0.578-0.711) | < 0.001 | >1.71 | 67.30% | 55.10% |
| **Females** |   |   |   |   |   |
| CMI | 0.681(0.613-0.749) | < 0.001 | >0.64 | 80.80% | 47.90% |
| LAP | 0.676(0.609-0.744) | < 0.001 | >45.26 | 72.70% | 58.50% |
| BMI | 0.600(0.528-0.671) | 0.008 | >21.75 | 90.00% | 26% |
| WC | 0.587(0.516-0.659) | 0.021 | >75.5 | 89% | 26.80% |
| WHtR | 0.599(0.528-0.671) | 0.009 | >0.55 | 61.60% | 57.00% |
| TG/HDL-C | 0.671(0.601-0.740) | < 0.001 | >1.915 | 55.60% | 74.00% |

**Table 3** AUC for indexes to discriminate microalbuminuria in females and males

Abbreviations: AUC area under the ROC curve, 95% CI 95% confidence interval, CMI cardiometabolic index, LAP lipid accumulation product, BMI body mass index, WC waist circumference, WHtR waist to height ratio, TG/HDL-C triglyceride to high density lipoprotein cholesterol ratio

a indicates a significant larger as compared to BMI;
b indicates a significant larger as compared to WC;
c indicates a significant larger as compared to WHtR;